2011/10/10 by Abderrahim Najaoui, Tamam Bakchoul, Johanna Stoy +6 · 2 citations
Business, Management and Accounting · #Auditing, Earnings Management, Governance #Financial Reporting and Valuation Research
paper · doi:10.1111/j.1600-0609.2011.01718.x
In a significant number of patients with chronic ITP, platelet autoantibodies are capable of activating the classical complement pathway. CF is even present in ITP sera without detectable autoantibodies, indicating that current techniques for autoantibody detection may be insufficient. The major targets for complement-fixing autoantibodies in ITP are GP IIb/IIIa and GP Ib/IX.